Sinclair Pharma Live Discussion

winningstreak 27 Jan 2015

Re: Rns-Trading Update Re my previous message, I should have said: 'when an increase in salesof £7.5m brings about a balance sheet net-cash shortfall of £4m, then where can be the profit?' In short and perhaps over-simplistic: the £7.5m extra sales cost £7.5m + £4m = £11.5m to achieve. But again, can anyone throw a less negative light on this?WS

winningstreak 27 Jan 2015

Re: Rns-Trading Update Revenues rose by £7.5m, but net-debt rose by £4m. I may be seeing thisover-simplistic but when it costs £4m to bring about gross sales of £7.5m,then where can be the profit? Can anyone cheer me up here?WS

ArianParod 27 Jan 2015

Rns-Trading Update RNS Number : 1839DSinclair IS Pharma PLC27 January 2015Trading UpdateLondon, 27 January 2015 Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group", the international specialty pharma company, announces a trading update for the six months ended 31 December 2014 ahead of the publication of interim results on 17 February 2015.The Group continues to perform well and in line with the Board's expectations. Revenues for the six months ended 31 December 2014 were GBP32.0 million, compared to GBP24.5 million for the same period last year representing reported growth of 31% and 37% on a constant currency basis. Revenues from the Group's aesthetic portfolio grew strongly to GBP13.6 million (43% of total revenues) with the recently acquired brands Silhouette, Perfectha and Ellansé all contributing significantly as detailed below.Silhouette(R) sales reached GBP2.7 million in the first half, representing growth of 52% (at constant currency) over the same period in 2013 (pre-acquisition). The Group has successfully repatriated direct rights for Silhouette(R) in the UK and France during H1 and in Germany from January 2015, and expects to conclude negotiations in Spain this month.Perfectha(R) delivered revenues of GBP3.7 million in the first half, with a strong performance in Europe where the Group has launched Perfectha(R) through all Sinclair's direct operations. Revenue in these territories grew to GBP0.8 million from GBP0.2 million in the same period in 2013 (pre-acquisition). Ellansé(TM) contributed revenues of GBP1.8 million in the first half, slightly below Board expectations but affected by distributor stocking patterns particularly in Korea and Russia. Sculptra revenues at GBP2.3 million were ahead of management expectations.Q2 trends in the Aesthetics franchise as a whole were particularly encouraging. The growth rate of the Aesthetics franchise has accelerated through the first half following an initial focus on revamping training, education and PR programmes. After a very successful Worldwide Experts Meeting held in Barcelona in October which was attended by almost 1,300 physicians, sales of Silhouette(R) have accelerated growing by 156% (at constant currency) in the final three months of 2014 over the previous quarter and Silhouette(R) training courses are currently oversubscribed. In Western Europe, the number of active Perfectha(R) users has increased by over 120% from around 450 users in June 2014 to over 1,000 by December 2014 and the number of active Ellansé(TM) users also doubled to 400 over the same period.During the first half, the 510(k) application for Silhouette(R) Instalift was filed in the US. The file is being reviewed by the FDA and management expect approval in 2015. Approval had been envisaged for Russia during H1 FY15 but due to political factors this is now viewed as unlikely in the near term.Country operations performed strongly in H1 reaching revenues of GBP17.8 million (H1 FY14 GBP16.7 million). Importantly aesthetic sales contributed revenues of GBP6.0 million with all brands performing well. The launch of Ellansé(TM) by Sinclair in France and Spain has been very well received with Ellansé(TM) sales in Sinclair direct territories increasing to GBP0.5m from GBP0.2m in the same period in 2013 (pre-acquisition).International operations revenues reached GBP14.2 million (H1 FY14 GBP7.8 million) with the addition of revenues from the acquired aesthetic brands as well as from continuing growth of Atopiclair(R), Papulex(R) and Kelostretch(R) in Asia. Partner stocking patterns and visibility on international orders provides confidence of continuing strong growth for the full year in the International business.EBITDA for the period is expected to be in line with the Board's expectations. Historical seasonality in both Sinclair's sales and marketing spend produces higher sales in the second half. The Board expects this trend to continue, noting the industry tende

ArianParod 09 Jan 2015

Investor presentation rns Read and DigestTIDMSPHRNS Number : 8408BSinclair IS Pharma PLC09 January 2015Posting of an updated investor presentationLondon, 9 January 2015 - Sinclair IS Pharma plc (AIM:SPH.L) ("the Company", the international specialty pharmaceutical company, announces that, ahead of JPMorgan's 33(rd) Healthcare Conference in San Francisco, its updated investor presentation is now available on the Company's website at www.sinclairispharma.com.

ArianParod 08 Jan 2015

Re: Big feature on our product EVER, and it's so quick you really can do it in your lunch hour! Helen Carroll for the Daily Mail225 07 Jan 2015, updated 07:48 08 Jan 2015+13FacebookTwitterClick to openPinterestGoogle PlusRedditStumble UponDigg itLinkedInEmailClick to close114shares148Threadlifts are the new 'non-surgical' facelifts available It takes just half-an-hour and there is no recovery time Winner of 2013's The Apprentice, Leah Totton, offers the treatment at her London clinic  Helen Carroll has put the new treatment to the testTake a look at these two photos. Can you see any difference between them? A little, but not too much? Good, that is exactly how it should be.The pictures were taken a week apart — I think you’ll agree that in the second one, I look a little sharper, fresher, more alive.Nothing too revolutionary or extreme, though. In fact, most people have assumed I’ve just had a really lovely, relaxing Christmas break. Which is precisely what I intended.Scroll down for video +13Before: Helen, 46, (pictured) went in for the new threadlift treatment at winner of The Apprentice Dr Leah Tottton's clinic in London before the school-run one dayYou see, a few weeks ago, before the school-run, I nipped out for a threadlift — known in the cosmetic surgery world as a ‘non-surgical’ or ‘lunchtime’ facelift — at the London clinic of Dr Leah Totton, the 25-year-old winner of 2013’s The Apprentice. It’s said to be the most furtive, discreet and effective facelift of all.MORE...Would YOU do urban yoga? Artist performs gravity-defying poses from lampposts, scaffolding and a basketball hoop'It was painful - but most women experience worse victim blaming': Lena Dunham details the critical reaction to her alleged assault during Today show appearanceAmerican Apparel implements new ethics code demanding staff seek approval to date their colleagues - one month after CEO was fired over sexual assault claims My surgeon, Dr Roberto Pizzamiglio, trained Leah, along with hundreds of other medics, in how to perform the Silhouette Soft lift, in which fine threads with tiny cones along the length of them are sewn into the face, beneath the subcutaneous layer of fat, with a needle, then pulled tight, gently lifting sagging skin.As it takes just half-an-hour and there is no recovery time, the procedure, which is available at clinics the length and breadth of the country for around £1,200, could be — and frequently is — performed during a lunch break, leaving colleagues none the wiser.+13After: Helen, 46, (pictured) underwent the half hour procedure, which has no recovery time, and was thrilled with the resultsIn fact, if you decided to greet inevitable comments like ‘Gosh, you look well’ and ‘You must tell me which foundation you use’ with a knowing smile, no one need ever know you’d succumbed to a secret moment of vanity.While I’m all for gilding the lily (I never leave home without a good smearing of make-up and regularly have my grey hair highlighted), I never imagined I would go so far as to have foreign bodies inserted in my face in my quest for eternal youth.But I became far more receptive to the idea a few months ago when, aged 46, I was shown an alarmingly jowly profile photograph of myself, taken by my ten-year-old daughter Isobel. I’d not seen myself in profile for some time and struggled with the harsh truth: my face, like the rest of me, was heading south.+13Dr Roberto Pizzamiglia (left) and Dr Leah Totton (right) performed the threadlift procedure on Helen at The Apprentice winner's clinic in London Shortly afterwards, while washing up, I caught sight of my reflection in the kitchen window and recoiled in shock, actually believing I’d seen a vision of my mother, who died six years ago aged 82.A more public low-point followed one evening when, on my way home from work, a woman in her 30s stood up to offer me her seat on the Tube. Not so long ago, that act of kindness

ArianParod 08 Jan 2015

Big feature on our product Article in todays Daily Mail on sillhoette soft

Hawk Eye32 09 Dec 2014

Trading Activity Is the 4 trades taken place today an indication that there could be possible buyers in the wings, ready to move in soon?

Ambiorix1 05 Dec 2014

Re: Today FDA discusses gram-negative in... Thank you gobbie for this information,I definitely overlooked this hurdle.Have a nice weekend.Ambiorix.

gobbie 05 Dec 2014

Re: Today FDA discusses gram-negative infect... AmbiorixFlammacerium cannot be approved in the US until it has been submitted for regulatory approval. The orphan drug designation may help get a more rapid approval and also longer market exclusivity but the it has not yet been submitted so we are a good way away from any approval. I attach the key paragraph from the news release back in April which details thisFlammacerium® must now be subject to the FDA regulatory process to gain marketing approval in the USA. While the expected time to filing for this approval remains uncertain and is dependent on the regulatory requirements to be finally determined, US approval would be expected to provide material upside to Sinclair's earnings in future.

Ambiorix1 05 Dec 2014

Today FDA discusses gram-negative infections... In March Incyte’s Jakafi got an orphan-drug status from the FDA, and so did Sinclair Pharma for Flammacerium. Yesterday, the FDA gave Incyte the official green light. In today’s meeting the FDA is, among other items, discussing Aerobic Gram-negative Infections with limited Treatment options. This is what Flammacerium is doing for burn wounds. Could this be the day of days for Sinclair? If it is, we just might get some good news by tomorrow morning. But if not, the waiting should not be long anymore.Ambiorix.

Ambiorix1 04 Dec 2014

Re: Old but important news in this conte... This is the link:[link]

Eggbaconandbubble 03 Dec 2014

Re: Old but important news in this context..... When did that little gem get mentioned Ambriorix?

Ambiorix1 28 Nov 2014

Old but important news in this context... I recently came across this remarkable little bit of news:… FDA authorizes emergency use of unapproved medicationThe massive number of causalities from this catastrophic event (09/11/2011) also prompted the FDA to permit use of an investigational cream for treating burns. Solvay Pharmaceuticals, located in Marietta, Ga., shipped 3,000 pounds of sulfadiazine/cerium (Flammacerium) to New York hospitals after FDA approved a label and a protocol. Not yet approved by FDA, sulfadiazine/cerium is in phase III clinical trials in the United States and is currently marketed in Europe for the treatment of severe burns….Since Sinclair got an Orphan drug status from the FDA for Flammacerium in March, a decision must probably be on the way soon, and as it is likely to be a positive one, this would make Sinclair an even more attractive little bride. Ambiorix.

winningstreak 27 Nov 2014

Re: Upto 10 potential buyers Baconegg - I think it is more a case of Rothschild managing the financial side ofany sale, not finding a buyer.ws

Madoff Jnr 26 Nov 2014

If any company out there wants my/our company then they can damn well pay for it-especially Nestle's.....! 60(p) plus good will,so lets say £1-20 then I'll consider..........Madoff Jnr x